| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $1.1M | +127.7% | +390.6% |
| SG&A Expense | $151.5M | — | — |
| Operating Income | -$152.6M | — | — |
| Net Income | -$152.6M | — | — |
| EPS (Basic) | -$0.76 | -7500.0% | -7500.0% |
| EPS (Diluted) | -$0.76 | -7500.0% | -7500.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $85K | — | — |
| Current Assets | $85K | +501.0% | +139.9% |
| Total Assets | $774K | +37.6% | -91.3% |
| Current Liabilities | $10.0M | +21.3% | +52.1% |
| Total Liabilities | $15.4M | +37.7% | +62.1% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$2.3M | — | — |
| Financing Cash Flow | $2.3M | — | — |
| -$14.6M |
| -31.0% |
| -54.5% |